GlassScriptPhysician profile
Bert Anthony Coppotelli
NPI 1629070941
$1,524.76
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $615 · 2021: $324 · 2023: $52.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $52.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $52.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $330.95 | 2019-2021 | |
| Glaxosmithkline, LLC. | $231.92 | 2019-2023 | Arexvy |
| Allergan, INC. | $192.87 | 2020 | |
| Pfizer INC. | $154.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $97.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $85.63 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.58 | 2019 | |
| Astellas Pharma US INC | $52.33 | 2019 | |
| Eisai INC. | $51.17 | 2020-2021 | |
| Abbvie INC. | $45.66 | 2021-2023 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.49 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $41.20 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $37.25 | 2021 | |
| Merck Sharp & Dohme LLC | $25.61 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $23.31 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $20.50 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bert Coppotelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.